title: [Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
abstract: OBJECTIVE
  The aim of this study was to analyze the efficacy and safety of paclitaxel liposomal and docetaxel for neoadjuvant chemotherapy of breast cancer.
  
  
  METHODS
  We retrospectively analyzed the clinical data of 188 operable patients with breast cancer who received neoadjuvant chemotherapy. According to the treatment regimens, they were divided into the group of paclitaxel liposome (86 patients) and group of docetaxel (102 patients) treatment. All the patients received a combination therapy with epirubicin and cyclophosphamide, i.e. neoadjuvant chemotherapy with three drugs, 21 days as a cycle, and a total of 6 cycles. Surgery was carried out three weeks after the end of chemotherapy, and the chemotherapy efficacy and adverse reaction of both groups were evaluated.
  
  
  RESULTS
  Pathological complete response (pCR) rate in the paclitaxel liposome group and docetaxel group was 10.5% and 9.8%, respectively, the objective response rate (ORR) was 80.2% and 79.4%, respectively, and the disease control rate (DCR) was 95.3% and 93.1%, respectively, showing a non-significant difference in therapy efficacy between the two groups (P > 0.05). Safety analysis indicated that all the occurrence rates of skin and nail toxic reaction, body fluid retention, oral mucositis, allergic reaction (such as facial blushing, chest distress, palpitation, dyspnea. etc.), and grade III-IV leukopenia and neutropenia in the paclitaxel liposome group were significantly lower than that of the docetaxel group (all P < 0.05).
  
  
  CONCLUSIONS
  Compared with docetaxel, paclitaxel liposome has the same anti-tumor efficacy, but causes fewer and milder adverse reactions with a higher safety in the neoadjuvant chemotherapy for breast cancer.
authors.affiliation: The 3rd Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Key laboratory of Breast Cancer Prevention and Therapy, Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Su
authors.affiliation: The 3rd Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Key laboratory of Breast Cancer Prevention and Therapy, Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Sheng
authors.initials: S
authors.lastname: Zhang
authors.affiliation: The 3rd Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Key laboratory of Breast Cancer Prevention and Therapy, Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Li
authors.affiliation: The 3rd Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Key laboratory of Breast Cancer Prevention and Therapy, Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
authors.forename: Xiaomeng
authors.initials: X
authors.lastname: Hao
authors.affiliation: The 3rd Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Key laboratory of Breast Cancer Prevention and Therapy, Tianjin, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China; Email: zhangjin@tjmuch.com.
authors.forename: Jin
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D000077143:Docetaxel; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008081:Liposomes; D020360:Neoadjuvant Therapy; D009503:Neutropenia; D017239:Paclitaxel / Q000627:therapeutic use; D012074:Remission Induction; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D008081:Liposomes; D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D017239:Paclitaxel